ES2609040T3 - Aminopirimidinas como inhibidores de Syk - Google Patents
Aminopirimidinas como inhibidores de Syk Download PDFInfo
- Publication number
- ES2609040T3 ES2609040T3 ES10801736.9T ES10801736T ES2609040T3 ES 2609040 T3 ES2609040 T3 ES 2609040T3 ES 10801736 T ES10801736 T ES 10801736T ES 2609040 T3 ES2609040 T3 ES 2609040T3
- Authority
- ES
- Spain
- Prior art keywords
- free base
- optionally substituted
- alkyl
- co2h
- isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
Abstract
Un compuesto de formula (I) o una sal farmaceuticamente aceptable del mismo:**Fórmula** en la que p es de 0 a 4; q es 0, 1 o 2; Cy se selecciona entre cicloalquilo C4-7, oxetanilo, pirrolidinilo, piperidinilo y azepanilo; R1 se selecciona entre H, alquilo C1-4, haloalquilo C1-4, cicloalquilo C3-6 y Oalquilo C1-4; R4 se selecciona entre H, alquilo C1-4 y cicloalquilo C3-4; Ry(a) es aminometilo, OH, OCH3, OCH2CH2OH, F, CN, CO2Ra(a), CONRb(a)Rc(a), NRa(a)Ra(a), NHC(O)alquilo C1-3 (opcionalmente sustituido con OH), NHC(O)NH2, NHSO2NH2, NHSO2alquilo C1-3 o NHSO2haloalquilo C1-3; Rz(a) se selecciona entre (A) alquilo C1-4 opcionalmente sustituido con uno a tres grupos seleccionados independientemente entre OH, NH2, CN, CO2Ra(a) y CONH2, (B) fluoroalquilo C1-3, (C) halogeno, (D) CN, (E) COalquilo C1-4 (opcionalmente sustituido con uno o dos grupos seleccionados independientemente entre ORa(a), CN, CO2Ra(a), CONRa(a)Ra(a) y NRa(a)Ra(a)), (F) CO-fenilo (opcionalmente sustituido con uno o dos grupos seleccionados independientemente entre etinilo, CO2Ra(a), CN, F y OH), (G) CO-cicloalquilo C3-6 (opcionalmente sustituido con OH o CO2Ra(a)), (H) alquil C0-3-CO2Ra(a), (I) -C(O)NRb(a)Rc(a), (J) -ORa(a), (K) -OC(O)Ra(a), (L) -NRb(a)Rc(a), (M) -NHC(O)alquilo C1-4 (opcionalmente sustituido con uno a tres OH o un CONRa(a)Ra(a)), (N) -NHSO2alquilo C1-3, (O) -NHSO2NH2, (P) oxo, (Q) 1,3,4-oxadiazol-2(3H)-ona, (R) 1,2,4-oxadiazol-5(4H)-ona, (S) SO2NH2, (T) SO2alquilo C1-3, (U) SO2haloalquilo C1-3 y (V) SO2Ph; Ra(a) es H o alquilo C1-4; Rb(a) y Rc(a) se seleccionan independientemente entre (A) H, (B) cicloalquilo C3-6 opcionalmente sustituido con OH, (C) heteroarilo seleccionado entre imidazolilo, piridilo e indolilo, (D) tetrahidrofuranilo, (E) bencilo, (F) fenilo opcionalmente sustituido con uno o dos grupos seleccionados independientemente entre (CH2)0-2OH y F, (G1) alquilo C1-4 y (G2) haloalquilo C1-4, en donde (G1) y (G2) estan cada uno opcionalmente sustituido con uno a tres grupos seleccionados independientemente entre (i) OH, (ii) cicloalquilo C3-6 opcionalmente sustituido con uno o dos grupos seleccionados independientemente entre alquilo C1-4, CONH2, CO2H y CH2OH, (iii) CONH2, (iv) SO2NH2, (v) SO2alquilo C1-4, (vi) heterociclilo monociclico de 4 a 7 miembros opcionalmente sustituido con uno o dos grupos seleccionados independientemente entre oxo, (CH2)0-2OH y alquilo C1-4, (vii) un heteroarilo de 5 o 6 miembros opcionalmente sustituido con uno o dos grupos seleccionados independientemente entre carboxi, (CH2)0-2OH y alquilo C1-4, (viii) CN, (ix) Oalquilo C1-4, (x) CO2H, (xi) NRa(a)C(O)alquilo C1-4, (xii) fenilo opcionalmente sustituido con uno o dos grupos seleccionados independientemente entre (CH2)0-2OH, SO2NH2, CF3, F y Cl, (xiii) 1-pirrolidinilo opcionalmente sustituido con oxo, (xiv) 1-imidazolidinilo opcionalmente sustituido con oxo, (xv) 1-piperidinilo opcionalmente sustituido con oxo y (xvi) 4-morfolinilo; o Rb(a) y Rc(a) junto con el atomo de nitrogeno al que estan unidos forman un heterociclo de 6 o 7 miembros que tiene de 0 a 1 heteroatomo adicional seleccionado entre N, O y S, en donde dicho heterociclo esta opcionalmente sustituido con uno o dos grupos seleccionados independientemente entre oxo, CN, (CH2)0-2OH, acetilo, bencilo, SO2alquilo C1-4, CONH2, metoximetilo, carboximetilo, CO2Ra(a) y alquilo C1-4.
Description
5
15
25
35
45
55
65
1-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclopropanocarboxamida; 4-{[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]carbonil}piperazin-2-ona; 2-{[2-({3-metil-5-[2-(1,1,1-trifluoro-2-hidroxipropan-2-il)-1,3-tiazol-5-il]fenil}amino)-pirimidin-4-il]oxi}acetamida; 1-(5-{3-[(4-metoxipirimidin-2-il)amino]-5-metilfenil}-1,3-tiazol-2-il)ciclobutanol; 1-(5-{3-metil-5-[(4-metilpirimidin-2-il)amino]fenil}-1,3-tiazol-2-il)ciclobutanol; 1-{5-[3-metil-5-(pirimidin-2-ilamino)fenil]-1,3-tiazol-2-il}ciclobutanol; 1-(5-{3-[(4-ciclobutilpirimidin-2-il)amino]-5-metilfenil}-1,3-tiazol-2-il)ciclobutanol; 1-(5-{3-[(4-ciclopentilpirimidin-2-il)amino]-5-metilfenil}-1,3-tiazol-2-il)ciclobutanol; 1-(5-{3-[(4-ciclohexilpirimidin-2-il)amino]-5-metilfenil}-1,3-tiazol-2-il)ciclobutanol; 1-(5-{3-[(4-etoxipirimidin-2-il)amino]-5-metilfenil}-1,3-tiazol-2-il)ciclobutanol; 1-(5-{3-[(4-etoxipirimidin-2-il)amino]-5-metilfenil}-1,3-tiazol-2-il)ciclobutanol; 1-[5-(3-metil-5-{[4-(1-metiletoxi)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]-ciclobutanol; cis-4-(aminometil)-1-(5-{3-metil-5-[(4-metilpirimidin-2-il)amino]fenil}-1,3-tiazol-2-il)ciclohexanol; trans-4-(aminometil)-1-(5-{3-metil-5-[(4-metilpirimidin-2-il)amino]fenil}-1,3-tiazol-2-il)ciclohexanol; 4-(aminometil)-1-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexanol; 4-(2-aminoetil)-1-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexanol; trans-4-(hidroximetil)-1-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]aminofenil)-1,3-tiazol-2-il]ciclohexanol; 4-(hidroximetil)-1-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexanol; cis-4-(hidroximetil)-1-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexanol; 4-(hidroximetil)-1-(5-{3-metil-5-[(4-metilpirimidin-2-il)amino]fenil}-1,3-tiazol-2-il)ciclohexanol; ácido 1-amino-4-hidroxi-4-(5-{3-metil-5-[(4-metilpirimidin-2-il)amino]fenil}-1,3-tiazol-2-il)ciclohexanocarboxílico; ácido cis-[3-hidroxi-1-metil-3-(5-{3-metil-5-[(4-metilpirimidin-2-il)amino]fenil}-1,3-tiazol-2-il)ciclohexil]acético; ácido trans-[3-hidroxi-1-metil-3-(5-{3-metil-5-[(4-metilpirimidin-2-il)amino]fenil}-1,3-tiazol-2-il)ciclohexil]acético; ácido {cis-4-hidroxi-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexil}acético; ácido {trans-4-hidroxi-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexil}acético; 3-hidroxi-3-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexanocarboxilato de etilo; ácido (1R)-{(3S)-3-hidroxi-1-metil-3-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2il]ciclohexil}acético; ácido (1R)-{(3R)-3-hidroxi-1-metil-3-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2il]ciclohexil}acético; 4-hidroxi-4-(5-{3-metil-5-[(4-metilpirimidin-2-il)amino]fenil}-1,3-tiazol-2-il)-2-fenilciclohexanocarboxilato de etilo; ácido 3-{4-hidroxi-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexil}-2,2dimetilpropanoico; 4-(dimetilamino)-1-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenol)-1,3-tiazol-2-il]ciclohexanol; 5-hidroxi-5-(5-{3-metil-5-[(4-metilpirimidin-2-il)amino]fenil}-1,3-tiazol-2-il)azepan-2-ona; ácido 5-{4-hidroxi-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]piperidin-1-il}-5oxopentanoico; 2-metil 4-hidroxi-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]piperidin-1,2-dicarboxilato de 1-tercbutilo; 4-hidroxi-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]-2-(trifluorometil)piperidin-1carboxilato de tercbutilo; 4-hidroxi-2,3-dimetil-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2il]ciclohexanocarboxilato de etilo; (1S,4R)-3,3-dimetil-1-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenol)-1,3-tiazol-2-il]ciclohexano-1,4-diol; (1R,4S)-3,3-dimetil-1-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenol)-1,3-tiazol-2-il]ciclohexano-1,4-diol; 3-hidroxi-2,2-dimetil-3-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenol)-1,3-tiazol-2-il]ciclohexanona; cis-2,2-dimetil-1-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexano-1,3-diol; trans2,2-dimetil-1-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenol)-1,3-tiazol-2-il]ciclohexano-1,3-diol; (5S)-5-hidroxi-5-[5-(3-metil-5-{[4-(1-metiletil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]azepan-2-ona; (5R)-5-hidroxi-5-[5-(3-metil-5-{[4-(1-metiletil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]azepan-2-ona; cis-4-hidroxi-4-[5-(3-metil-5-{[4-(1-metiletil)pirimidin-2-il]amino}fenol)-1,3-tiazol-2-il]ciclohexanocarboxilato de tercbutilo; cis-4-hidroxi-4-[5-(3-metil-5-{[4-(1-metiletoxi)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexanocarboxilato de tercbutilo; ácido [cis-4-hidroxi-4-(5-{3-metil-5-[(4-metilpirimidin-2-il)amino]fenil}-1,3-tiazol-2-il)ciclohexil]acético; ácido [trans-4-hidroxi-4-(5-{3-metil-5-[(4-metilpirimidin-2-il)amino]fenil}-1,3-tiazol-2-il)ciclohexil]acético; ácido {4-hidroxi-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexil}acético; ácido (4-{4-hidroxi-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexil}fenil)acético; ácido 3-{4-hidroxi-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexil}propanoico; ácido cis3{4-hidroxi-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2il]ciclohexil}propanoico; ácido trans-3-{4-hidroxi-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2il]ciclohexil}propanoico; 3-{4-hidroxi-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexil}propanoato de etilo; ácido (1S,4R)-4-hidroxi-4-(5-{3-[(4-metoxipirimidin-2-il)amino]-5-metilfenil}-1,3-tiazol-2-il)-2,2dimetilciclohexanocarboxílico;
8
- 4B-11
- CF3 H +++ 395,0 Base Libre
- 4B-12
- CF3 CH3 +++ 409,1 Base Libre
- 4B-57
- CF3 CH3 +++ 535 Base Libre
TABLA 4C
- Ej.
- R1* X R3/R4 Actividad de rhSYK [M+H] + Obs. Forma(s)
- R2 = H
- 4C-1
- CF3 CH2CH2 H/H +++ 435,1 Base libre
- R2 = CH3
- 4C-2
- CH3 CH2 H/CH2NH2 (cis) +++ 410,2 Sal TFA
- 4C-3
- CH3 CH2 H/CH2NH2 (trans) +++ 410,2 Sal TFA
- 4C-4
- CF3 CH2 H/CH2NH2 +++, +++ 464,2 Base Libre Sal TFA
- 4C-5
- CF3 CH2 H/CH2CH2NH2 +++ 478,2 Sal TFA
- 4C-6
- CF3 CH2 H/CH2OH (trans) +++ 465,2 Base Libre
- 4C-7
- CF3 CH2 H/CH2OH +++ 465,2 Base Libre
- 4C-8
- CF3 CH2 H/CH2OH (cis) +++ 465,2 Base Libre
- 4C-9
- CH3 CH2 H/CH2OH +++ 411,2 Base Libre
- 4C-10
- CH3 CH2 NH2/CO2H +++ 440,0 Sal TFA
- 4C-11
- CH3 CH2 CH3/CH2CO2H (isómero 1) +++ 453,1 Sal TFA
- 4C-12
- CH3 CH2 CH3/CH2CO2H (isómero 2) +++ 453,1 Sal TFA
- 4C-14
- CF3 CH2 H/CH2CO2H (cis) +++ 493,1 Base Libre
- 4C-15
- CF3 CH2 H/CH2CO2H (trans) +++ 493,1 Base Libre
- 4C-17
- CH3 CH(iPr) H/CO2CH3 +++ 481,1 Base Libre
- 4C-21
- CF3 CH(CO2Et) H/H ++ 507,1, 507,2 Base Libre
- 4C-22
- CF3 C(CH3) (CH2CO2H) H/H (1R, 3S) +++ 507,1 Sal TFA
- 4C-23
- CF3 C(CH3) (CH2CO2H) H/H (1R, 3R) +++ 507,1 Sal TFA
- 4C-25
- CF3 CH(iPr) H/CO2CH3 ++ 535,0 Base Libre
- 4C-26
- CF3 CH2 H/CH2C(CH3)2CO2H +++ 535,2 Sal TFA
- 4C-33
- CF3 CH2 H/N(CH3)2 +++ 478 Sal formiato
- * R1 está en la posición 4 del anillo de pirimidina, a menos que se indique otra cosa.
TABLA 4D
49
- Ej.
- R1 R2 X R3 Actividad de rhSYK [M+H] + Obs. Forma(s)
- 4D-1
- CF3 H CH2 C(O)CH3 +++ 464,3 Base Libre
- 4D-4
- CF3 H CH2 CO2Et +++ 494,1 Base Libre
- 4D-5
- CF3 H CH2 iPr ++ 464,1 Base Libre
- 4D-6
- CF3 H CH2 C(O)Ph +++ 526,1 Base Libre
- 4D-7
- CH3 CH3 CH2C(O) (se formó la lactama) H +++ 410,2 Base Libre
- 4D-13
- CF3 CH3 CH2 C(O)(CH2)3CO2H +++ 550,1 Sal Formiato
- 4D-14
- CF3 CH3 CH(CO2CH3) CO2C(CH3)3 ++ 594,1 Base Libre
- 4D-15
- CF3 CH3 CH(CF3) CO2C(CH3)3 ++ 604,1 Base Libre
Ejemplo 6 (Referencia)
2,2,2-trifluoro-1-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]etanol
Etapa 1: Se añadió lentamente el INTERMEDIO 4 (500 mg, 1,487 mmol) en THF (7,4 ml) a LDA (1,8 M, 2478 µl, 4,46 mmol) enfriado previamente a -78 ºC durante 5 min con agitación. La mezcla de reacción se dejó en
10 agitación durante 30 min y después se trató con trifluoroacetato de etilo (0,27 ml, 2,2 mmol). Después de 1 h, la reacción se interrumpió añadiendo 5 ml de una solución acuosa saturada de NH4Cl, y la mezcla se calentó a temperatura ambiente. La mezcla se extrajo con acetato de etilo, y se lavó con una solución saturada de NaHCO3. La capa orgánica se secó sobre Na2SO4 anhidro, se filtró, se concentró y se purificó por cromatografía ultrarrápida para dar 2,2,2-trifluoro-1-[5-(3-metil-5- {[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]etano
15 1,1-diol (513 mg, 1,139 mmol, rendimiento del 77 %) en forma de un aceite incoloro. APCI: [M + H]+ m/z 451,0. Etapa 2: Se añadió borohidruro sódico (41,6 mg, 1,099 mmol) al producto de la Etapa 1 (450 mg, 0,999 mmol) en MeOH (3,3 ml) a 0 ºC. Después de agitar durante 3 h, la reacción se vertió en un embudo de decantación que contenía acetato de etilo y NaHCO3 acuoso saturado. Las capas se separaron y la capa orgánica se lavó con agua y salmuera, se secó sobre sulfato sódico anhidro y se concentró. El residuo se purificó por cromatografía
50
- 33A-14
- 4-CF3 CH3 CO2Me/NHC(O)CH3 +++ 550,1 Base Libre
- 33A-15
- 4-CF3 CH3 CO2H/NHC(O)CH3 +++ 536,1 Sal TFA
- 33A-16
- 4-CF3 CH3 H/CH2CO2H (trans) +++ 493 Sal formiato
- 33A-18
- 4-CF3 CH3 H/CH2CH2CO2H +++ 507,2 Base Libre
- 33A-19
- 4-CF3 CH3 H/CH2CH2CO2H (cis) +++ 507,2 Base Libre
- 33A-20
- 4-CF3 CH3 H/CH2CH2CO2H (trans) +++ 507,2 Base Libre
- 33A-21
- 4-CF3 CH3 H/CH2CH2CO2CH2C H3 +++ 535,2 Base Libre
- 33A-22
- 4-CF3 CI H/CO2H (trans) +++ 499,1 Base Libre
- 33A-23
- 4-CF3 H H/CO2H (trans) +++ 465,0 Base Libre
- 33A-24
- 4-CF3 H H/CO2H (cis) +++ 465,0 Base Libre
- 33A-25
- 4-CF3 H H/CO2Et (cis) +++ 493,1 Base Libre
- 33A-26
- 4-CF3 H H/CO2Et (trans) ++ 493,1 Base Libre
- 33A-27
- 4-CF3 H CH3/CO2H (trans) +++ 479,1 Base Libre
- 33A-28
- 4-CF3 H CH3/CO2H (cis) +++ 479,1 Base Libre
- 33A-29
- 4-iPr CH3 H/CO2C(CH3)3 (cis) ++ 509,2 Base Libre
- 33A-30
- 4-CH3 CH3 H/CO2H (cis) +++ 425,1 Base Libre
- 33A-31
- 4-CH3 CH3 H/CO2H (trans) +++ 425,1 Base Libre
- 33A-32
- 4-CH3 CH3 H/CH2CO2H (cis) +++ 439,1 Base Libre
- 33A-33
- 4-CH3 CH3 H/CH2CO2H (trans) +++ 439,0 Base Libre
- 33A-34
- 4-O-iPr CH3 H/CO2C(CH3)3 (cis) ++ 525,2 Base Libre
- 33A-35
- 4-OCH3 CH3 H/CO2H (cis) +++ 441,1 Base Libre
- 33A-36
- 4-OCH3 CH3 H/CO2H (trans) +++ 441,1 Base Libre
- 33A-37
- 4-OCH3 CH3 CH3/CO2H (cis) +++ 455,1 Base Libre
- 33A-38
- 4-OCH3 CH3 CH3/CO2H (trans) +++ 455,1 Base Libre
- Fórmula B; R5 = H
- 33A-54
- CF3 CH3 H/CO2H (trans) +++ 507 Base Libre
- 33A-59
- CF3 c-Pr H/CO2H (enantiómero 1) +++ 533,2 Base Libre
- 33A-60
- CF3 c-Pr H/CO2H (enantiómero 2) +++, +++ 533,2 Base Libre, Sal TFA
- 33A-61
- CF3 c-Pr H/CO2CH3 +++ 547,2 Base Libre
- 33A-62
- CF3 c-Pr H/CO2H +++ 533,2 Sal TFA
- 33A-65
- CF3 H H/CO2CH3 ++ 507,1 Base Libre
- 33A-66
- CF3 H H/CO2H (cis, enantiómero 1) +++ 493 Base Libre
- 33A-67
- CF3 H H/CO2H (cis, enantiómero 2) +++ 493 Base Libre
- 33A-68
- CH3 CH3 H/CO2H (cis) +++ 452,1 Base Libre
- 33A-69
- CH3 CH3 H/CO2CH3 (cis) +++ 467,2 Base Libre
- 33A-70
- c-Pr CH3 H/CO2CH3 +++ 493,2 Base Libre
- 33A-71
- c-Pr CH3 H/CO2H +++ 479,2 Base Libre
- 33A-72
- OCH3 CH3 H/CO2H (isómero 1) +++ 469,1 Base Libre
- 33A-73
- OCH3 CH3 H/CO2H (isómero 2) +++ 469,1 Base Libre
- Fórmula B; R5 = CH3
- 33A-75
- CF3 CH3 H/CO2H +++ 521 Base Libre
- 33A-76
- CF3 CH3 H/CO2H (isómero 1) +++ 521 Base Libre
- 33A-77
- CF3 CH3 H/CO2H (isómero 2) +++ 521 Base Libre
- 33A-78
- CF3 CH3 H/CO2H (isómero 3) +++ 521 Base Libre
TABLA 33B
60
- Ej.
- X Y R3/R4 Actividad de rhSYK [M+H]+ Obs. Forma(s)
- R1 = CF3, R5 = H
- 33B-1
- Enlace Enlace H/CO2H +++ 451,0 Sal amonio
- 33B-3
- C(CH3)2 Enlace H/CO2H +++ 493 Base Libre
- 33B-4
- C(CH3)2 Enlace H/CO2H (isómero 2) +++ 493 Base Libre
- 33B-5
- C(CH3)2 Enlace H/CO2H (isómero 4) +++ 493 Base Libre
- 33B-6
- C(CH3)2 Enlace H/CO2H (isómero 1) +++ 493 Base Libre
- 33B-7
- C(CH3)2 Enlace H/CO2H (isómero 3) +++ 493 Base Libre
- 33B-8
- C(CH3)2 CH2CH2 H/CO2H +++ 521 Base Libre
- 33B-9
- C(CH3)2 CH2CH2 H/CO2H (isómero 1) +++ 521 Base Libre
- 33B-10
- C(CH3)2 CH2CH2 H/CO2H (isómero 2) +++ 521 Base Libre
- 33B-11
- C(CH3)2 CH2CH2 H/CO2H (isómero 3) +++ 521 Base Libre
- 33B-12
- C(CH3)2 CH2CH2 H/CO2H (isómero 4) +++ 521 Base Libre
- 33B-13
- CH(OCH3) CH2 H/CO2H +++ 509 Base Libre
- 33B-14
- CH(OCH3) CH2 H/CO2H (cis,cis) +++ 509 Base Libre
- 33B-18
- CH(CH3) CH2 H/CO2H (isómero 1) +++ 493,1 Base Libre
- 33B-19
- CH(CH3) CH2 H/CO2H (isómero 2) +++ 493,2 Sal TFA
- 33B-20
- CH(CH3) CH2 H/CO2H (isómero 3) +++, +++ 493,1 Base Libre, Sal TFA
- 33B-21
- CH(CO2H) CH2 H/H +++ 479,1 Base Libre
- 33B-24
- CH(iPr) CH2 H/CO2H +++ 521 Base Libre
- 33B-22
- CH(iPr) CH2 H/CO2H (enantiómero 1) +++ 521 Base Libre
- 33B-23
- CH(iPr) CH2 H/CO2H (enantiómero 2) +++ 521 Base Libre
- 33B-24
- CH2 enlace H/CO2H +++ 465,0 Sal amonio
- 33B-25
- CH2 enlace H/CH2CO2H (trans, enantiómero 1)) +++ 479 Base Libre
- 33B-26
- CH2 enlace H/CH2CO2H (cis, enantiómero 1) +++ 479 Base Libre
- 33B-27
- CH2 enlace H/CH2 CO2H (trans, enantiómero 2) +++ 479 Base Libre
- 33B-28
- CH2 enlace H/CH2CO2H (cis, enantiómero 2) +++ 479 Base Libre
- R1 = CH3, R5 = H
- 33B-32
- CH(CH3) CH2 H/CO2H (isómero 1) +++ 439,2 Base Libre
- 33B-33
- CH(CH3) CH2 H/CO2H (isómero 2) +++ 439,2 Base Libre
- 33B-34
- CH(iPr) CH2 H/CO2H +++ 467 Base Libre
- 33B-35
- CH(iPr) CH2 H/CO2H (isómero 1) +++ 467 Base Libre
- 33B-36
- CH(iPr) CH2 H/CO2H (isómero 2) +++ 467 Base Libre
- 33B-37
- CH(Ph) CH2 H/CO2H +++ 501 Base Libre
- R1 = CF3, R5 = CH3
- 33B-38
- CH(CH3) CH2 H/CO2H (isómero 1) +++ 507 Sal TFA
- 33B-39
- CH(CH3) CH2 H/CO2H (isómero 2) +++ 507 Base Libre
- R1 = CF3, R5 = CH2CH3
- 33B-40
- CH(CH3) CH2 H/CO2H +++ 521 Sal TFA
- 33B-41
- CH(CH3) CH2 H/CO2H (isómero 1) +++ 521 Sal TFA
- 33B-42
- CH(CH3) CH2 H/CO2H (isómero 2) +++ 521 Sal TFA
Ejemplo 34 (Referencia)
4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohex-3-eno-1-carboxilato de etilo 61
Etapa 3: A 4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexanocarboxilato de etilo (0,60 g, 0,12 mmol) en tetrahidrofurano (0,61 ml) se le añadió hidróxido potásico (1,2 ml, 1 M en metanol) y la 5 reacción se agitó durante una noche a temperatura ambiente. Tras la finalización, la reacción se diluyó con diclorometano y se lavó dos veces con ácido clorhídrico (2 M en agua). La capa orgánica se secó a presión reducida para dar cloruro de 2-({3-[2-(4-carboxiciclohexil)-1,3-tiazol-5-il]-5-metilfenil}amino)-4-(trifluorometil)pirimidin-1-io (0,060 g, rendimiento del 85 %). MS ESI: [M+H]+ m/z 463,1. 1H RMN (500 MHz, DMSO-d6) δ 10,25 (s, 1H), 8,83 (d, J = 5,2, 1H), 8,06 - 7,81 (m, 2H), 7,44 (s, 1H), 7,27 (d, J = 5,8, 1H), 7,14 (s, 1H), 2,30 (s, 3H), 2,14 -2,04 (m, 1H), 2,03
10 - 1,83 (m, 4H), 1,82-1,61 (m, 3H), 1,55 -1,33 (m, 2H). Actividad de rhSYK = +++
Los siguientes ejemplos se prepararon de una manera análoga a la descrita en los Ejemplos 34-36.
TABLA 36A
- Ejemplo
- R1 X R2/R2' o R2+R2' --- Actividad de rhSYK [M+H] + Obs. Forma(s)
- R3 = R3' = H
- 36A-2
- CH3 CHCO2Et H/H individual ++ 491,1 Base Libre
- 36A-4
- H CHCO2H (trans) H/H individual +++ 449,1 Base Libre
- 36A-5
- H CHCO2Me (trans) H/H individual ++ 463,1 Base Libre
- 36A-8
- CH3 CH2 =O individual +++ 433,1 Base Libre
- 36A-10
- CH3 CH2CH2 =O individual +++ 447,1 Base Libre
TABLA 36B
- Ejemplo
- R Actividad de rhSYK [M+H]+ Obs. Forma(s)
- 36B-1
-
imagen59 +++ 434,1 Base Libre
- 36B-3
- +++ 448,1 Base Libre
63
{[4-hidroxi-4-(5-{3-[(4-metoxipirimidin-2-il)amino]-5-metilfenil}-1,3-tiazol-2-il)piperidin-1-il]sulfonil}carbamato de metilo (7 mg, 0,013 mmol, 10 %). MS ESI: [M + H]+ m/z 535,1. 1H RMN (600 MHz, CD3OD): δ 8,09 (d, J = 6,0 Hz, 1H); 7,91 (s, 1H); 7,88 (s, 1H); 7,38 (s, 1H); 7,08 (s, 1H); 6,23 (d, J= 6,0 Hz, 1H); 3,98 (s, 3H); 3,73 (m, 3H); 3,34 (m, 2H); 3,19 (m, 2H); 2,35 (s, 3H); 2,25 (m, 2H); 1,90 (m, 2H). Actividad de rhSYk = +++
5 4-Cloro-4-(5-{3-[(4-metoxipirimidin-2-il)amino]-5-metilfenil}-1,3-tiazol-2-il)piperidin-1-sulfonamida (18 mg, 0,036 mmol, 28 %). MS ESI: [M + H]+ m/z 495,2. 1H RMN (500 MHz, CD3OD): δ 8,09 (d, J = 6,0 Hz, 1H); 7,89 (s, 2H); 7,38 (s, 1H); 7,09 (s, 1H); 6,24 (d, J = 6,0 Hz, 1H); 4,37 (m, 1H); 3,99 (s, 3H); 3,97 (m, 1H); 3,68 (m, 1H); 3,36 (m, 1H); 2,35 (s, 3H); 2,19 (m, 2H); 1,94 (m, 2H). Actividad de rhSYK = +++
10 Los siguientes ejemplos se prepararon de una manera análoga a la descrita en los Ejemplos 47-54 para urea N,Ndisustituida (Ejemplo 47), t-butil carbamato de sulfamoílo disustituido (Ejemplo 48), diamida sulfúrica N,N,N'trisustituida (Ejemplo 49), sulfonamida N,Ndisustituida o ácido sulfámico (Ejemplo 50), amida (Ejemplo 51), urea N,N,N'-trisustituida (Ejemplo 52), azetidina Nalquilada, pirrolidina, piperidina o azepano (Ejemplo 53), y carbamato de sulfamoílo N,N,N'-trisustituido (Ejemplo 54).
15 TABLA 54A
- EJ.
- R1 R2 Actividad de rhSYK [M+H]+ Observado Forma(s)
- N = 1
- 54A-1
- CF3 -SO2-IPR +++ 542,1 Sal formiato
- 54A-2
- CF3 -SO2-CF3 +++ 568,1 Sal formiato
- 54A-4
- CF3 -C(O)ET +++ 492,1 Sal formiato
- 54A-5
- CF3 -C(O)CH2OH +++ 494,1 Sal formiato
- 54A-6
- CF3 -C(O)CH2CN +++ 503,1 Sal formiato
- 54A-7
- CF3 -C(O)CH2N(CH3)2 +++ 521,2 Sal formiato
- 54A-11
- CF3 -C(O)-C-PR +++ 504,1 Sal formiato
- 54A-12
- CF3 -C(O)NHC-HEX +++ 561,2 Sal formiato
- 54A-13
- CF3 -C(O)NH-IPR +++ 521,2 Sal formiato
- 54A-14
- CF3 -C(O)NH-NPR +++ 521,2 Sal formiato
- 54A-15
- CF3 -C(O)N(CH3)2 +++ 507,1 Base Libre
- 54A-16
- CF3 -SO2NH2 +++ 515,2 Base Libre
- 54A-19
- OCH3 -C(O)NH2 +++ 441,2 Base Libre
- 54A-20
- OCH3 H +++ 398,2 Base Libre
- 54A-21
- CF3 -C(O)CH(OH)CH3 (R) +++ 508,2 Sal formiato
- 54A-22
- CF3 -C(O)CH2CH2OH +++ 508,2 Base Libre
- 54A-23
- CF3 -C(O)CH2CH2CN +++ 517,2 Sal formiato
- 54A-24
- CF3 -CH2CF3 +++ 518,1 Base Libre
- 54A-25
- CF3 -C(O)CH2C(O)NH2 +++ 521,2 Sal formiato
- 54A-26
- CF3 -C(O)CH2C(O)2H +++ 522,1 Base Libre
- 54A-27
- CF3 -C(O)CH2CH(OH)CH3 +++ 522,2 Base Libre
- 54A-33
- CF3 -C(O)-(3-OH-CBU) +++ 534,2 Sal formiato
- 54A-34
- CF3 -C(O)-PH +++ 540,2 Sal formiato
- 54A-43
- CF3 -C(O)CH2-CO2ET +++ 550,2 Base Libre
- 54A-44
- CF3 -C(O)C(CH2OH)2CH3 +++ 552,2 Sal formiato
- 54A-54
- CF3 -C(O)-(1-CO2CH3)-CPR +++ 562,2 Base Libre
- 54A-55
- CF3 -C(O)-(4-C≡CH)PH +++ 564,2 Sal formiato
- 54A-56
- CF3 -C(O)-(4-CN)PH +++ 565,2 Sal formiato
- 54A-57
- CF3 -C(O)-(3-F, 4-OH)PH +++ 574,2 Sal formiato
- 54A-59
- CF3 -C(O)-(4-CO2CH3)PH +++ 604,2 Sal formiato
- 54A-61
- CF3 (CH2)3CH3 +++ 535,2 Base Libre
78 TABLA 54B
- 54A-70
- CF3 CH2CO2CH3 +++ 508,2 Base Libre
- 54A-71
- CF3 CH2CH2CO2CH3 +++ 522,2 Base Libre
- 54A-72
- CF3 CH(CH3)CO2CH3 +++ 522,2 Base Libre
- 54A-73
- CF3 (CH2)3CO2CH3 +++ 536,2 Base Libre
- N = 2
- 54A-74
- CF3 CH3 +++ 507,2 Base Libre
- 54A-75
- CF3 CH3 (Enantiómero 1) +++ 507,2 Base Libre
- 54A-76
- CF3 CH3 (Enantiómero 2) +++ 507,2 Base Libre
- 54A-78
- CF3 CH2CH2CH3 +++ 535,2 Base Libre
- 54A-79
- CF3 CH(CH3)2 +++ 535,2 Base Libre
- 54A-80
- CF3 CH2CO2ET +++ 579,2 Base Libre
- 54A-81
- CF3 (CH2)3CO2ET +++ 607,2 Sal TFA
- 54A-82
- CF3 CH2CH2F +++ 496,2 Sal TFA
- 54A-83
- CF3 CH2CO2H ++ 508,2 TFA SALT
- 54A-84
- CF3 CH2CH2CO2H +++ 522,2 Base Libre
- 54A-85
- CF3 CH2CF3 (Enantiómero 1) +++ 532,2 Base Libre
- 54A-86
- CF3 CH2CF3 (Enantiómero 2) +++ 532,2 Base Libre
- 54A-87
- CF3 CH2CF3 +++ 532,2 Sal TFA
- 54A-88
- CF3 CH2CH2CO2CH3 +++ 536,2 Sal formiato
- 54A-89
- CF3 CH2CO2C(CH3)3 +++ 564,2 Base Libre
- EJ.
- R1 R2 Actividad de rhSYK [M+H]+ Observado Forma(s)
- X = CH2
- 54B-2
- CF3 -C(O)NH2 (Enantiómero 1) +++ 465,1 Base Libre
- 54B-3
- CF3 -C(O)NH2 (Enantiómero 2) +++ 465,1 Base Libre
- 54B-4
- CF3 -C(O)O-TBU ++ 522,2 Base Libre
- 54B-5
- CF3 H +++ 422,2 Base Libre
- 54B-6
- CF3 -SO2NH2 +++ 501,1 Base Libre
- 54B-7
- CF3 -C(O)NH2 +++ 465,1 Base Libre
- 54B-10
- OCH3 -C(O)NH2 +++ 427,2 Base Libre
- 54B-11
- OCH3 H +++ 384,2 Base Libre
- 54B-12
- CH3 H +++ 368,2 Base Libre
- 54B-13
- CH3 -C(O)NH2 (racémico) +++ 411,2 Base Libre
- 54B-14
- CH3 -C(O)NH2 (enantiómero 1) +++ 411,2 Base Libre
- 54B-15
- CH3 -C(O)NH2 (enantiómero 2) +++ 411,2 Base Libre
- 54B-19
- CF3 CH2CH2OH +++ 466,1 Sal TFA
- 54B-20
- CF3 CH2C(O)NH2 +++ 479,1 Sal TFA
- 54B-21
- CF3 -C(O)CH2OH +++ 480,1 Sal TFA
- 54B-22
- CF3 -CH2CO2H +++ 480,2 Sal TFA
- 54B-24
- CF3 -CH2CO2CH3 +++ 494,2 Base Libre
- 54B-26
- CF3 -C(O)CH2C(O)NH2 +++ 507,2 Sal TFA
- 54B-28
- CF3 -C(O)CH(OH)CH2OH +++ 510,2 Sal TFA
- 54B-30
- CF3 -C(O)-(1-OH)-C-BU +++ 520,2 Sal TFA
- X = CHCO2H 54B-36) O CHCO2CH3 (54B-37)
- 54B-36
- CF3 CONH2 +++ 509,2 Sal TFA
- 54B-37
- CF3 CONH2 +++ 523,2 Base Libre
TABLA 54C
79 TABLA 54D
- EJ.
- R2 Actividad de rhSYK [M+H]+ Observado Forma(s)
- 54C-1
- H +++ 408,2 Base Libre
- 54C-2
- -C(O)NH2 +++ 451,1 Base Libre
- EJ.
- R1 R2 Actividad de rhSYK [M+H]+ Obs. Forma(s)
- 54D-1
- IPR H +++ 424,2 Base Libre
- 54D-2
- CF3 -C(O)CH3 +++ 492,2 Base Libre
- 54D-3
- IPR -(S)-C(O)CH(OH)CH3 +++ 496,2 Base Libre
- 54D-4
- IPR -C(O)CH(OH)CH3 +++ 496,2 Base Libre
- 54D-5
- CF3 -C(O)ET +++ 506,2 Base Libre
- 54D-6
- IPR -C(O)CH2C(O)NH2 +++ 509,2 Base Libre
- 54D-7
- IPR -C(O)CH2CO2H +++ 510,2 Base Libre
- 54D-8
- IPR -C(O)CH(OH)CH2OH +++ 512,2 Base Libre
- 54D-9
- CF3 -C(O)CH2CN +++ 517,2 Base Libre
- 54D-10
- CF3 -C(O)-CPR +++ 518,2 Base Libre
- 54D-12
- CF3 -C(O)CH2OCH3 +++ 522,2 Base Libre
- 54D-13
- CF3 -C(O)CH2CH2OH +++ 522,2 Sal formiato
- 54D-14
- CF3 -C(O)CH(OH)CH3 +++ 522,2 Sal formiato
- 54D-15
- IPR -C(O)CH2CH2C(O)NH2 +++ 523,2 Base Libre
- 54D-16
- CF3 -C(O)CH2CH2CN +++ 531,2 Base Libre
- 54D-20
- CF3 -C(O)CH2C(O)NH2 (enantiómero 1) +++ 535,2 Base Libre
- 54D-21
- CF3 -C(O)CH2C(O)NH2 (enantiómero 2) +++ 535,2 Base Libre
- 54D-22
- CF3 -C(O)CH2C(O)NH2 +++ 535,2 Base Libre
- 54D-23
- CF3 -C(O)CH2CH(OH)CH3 +++ 536,2 Sal formiato
- 54D-24
- CF3 -C(O)CH2CO2H +++ 536,2 Sal formiato
- 54D-25
- CF3 -C(O)CH2CO2H (Enantiómero 1) +++ 536,2 Base Libre
- 54D-26
- CF3 -C(O)CH2CO2H (Enantiómero 2) +++ 536,2 Base Libre
- 54D-27
- CF3 -C(O)CH(OH)CH2OH +++ 538,2 Sal formiato
- 54D-28
- CF3 -C(O)CH(OH)CH2OH (isómero 1) +++ 538,2 Sal formiato
- 54D-29
- CF3 -C(O)CH(OH)CH2OH (isómero 2) +++ 538,2 Sal formiato
- 54D-30
- IPR -C(O)CH2CO2ET +++ 538,2 Base Libre
- 54D-31
- IPR -C(O)C(CH2OH)2CH3 +++ 540,3 Sal TFA
- 54D-41
- CF3 -C(O)CH2CH2C(O)NH2 (enantiómero 1) +++ 549,2 Sal TFA
- 54D-42
- CF3 -C(O)CH2CH2C(O)NH2 (enantiómero 2) +++ 549,2 Sal TFA
80 TABLA 54E
- 54D-43
- CF3 -C(O)CH2CH2CO2H +++ 550,2 Sal TFA
- 54D-44
- CF3 -C(O)CH2C(CH3)2OH +++ 550,2 Sal formiato
- 54D-45
- CF3 -C(O)-PH +++ 554,2 Base Libre
- 54D-70
- CF3 -C(O)-(1-CO2H-CPR) +++ 562,2 Sal formiato
- 54D-71
- CF3 -C(O)-(2-CO2H-CPR) +++ 562,2 Sal formiato
- 54D-72
- CF3 -C(O)CH2CH2CO2CH3 +++ 564,2 Base Libre
- 54D-73
- CF3 -C(O)CH2CO2CH2CH3 +++ 564,2 Sal formiato
- 54D-74
- CF3 -C(O)CH2CO2CH2CH3 (enantiómero 1) +++ 564,2 Base Libre
- 54D-75
- CF3 -C(O)CH2CO2CH2CH3 (enantiómero 2) +++ 564,2 Base Libre
- 54D-77
- CF3 -C(O)CH(OH)C(CH3)2OH +++ 566,2 Sal formiato
- 54D-78
- CF3 -C(O)C(CH2OH)2CH3 +++ 566,2 Base Libre
- 54D-79
- CF3 -C(O)C(CH2OH)2CH3 (enantiómero 1) +++ 566,2 Sal TFA
- 54D-80
- CF3 -C(O)C(CH2OH)2CH3 (enantiómero 2) +++ 566,2 Sal TFA
- 54D-84
- CF3 -C(O)-(4-OH)PH +++ 570,2 Base Libre
- 54D-95
- CF3 -C(O)-(1-CO2CH3)-CPR +++ 576,2 Sal formiato
- 54D-98
- CF3 -C(O)CH2CH2C(O)N(CH3)2 +++ 577,2 Base Libre
- 54D-99
- CF3 -C(O)-(4-C≡CH)PH +++ 578,2 Base Libre
- 54D103
- CF3 -C(O)-(3-F, 4-OH)PH +++ 588,2 Base Libre
- 54D104
- CF3 -C(O)-(2-F, 5-OH)PH +++ 588,2 Base Libre
- 54D111
- CF3 -C(O)-(4-CO2CH3)-CHEX +++ 618,2 Base Libre
- 54D113
- IPR -C(O)CH2C(O)NH2 +++ 509,2 Sal TFA
- 54D115
- CF3 SO2NH2 +++ 529,1 Sal TFA
- 54D116
- CF3 SO2NH2 (Enantiómero 1) +++ 529,1 Base Libre
- 54D117
- CF3 SO2NH2 (Enantiómero 2) +++ 529,1 Base Libre
- 54D119
- CF3 C(O)NH2 (Enantiómero 1) +++ 493,1 Base Libre
- 54D120
- CF3 C(O)NH2 (Enantiómero 2) +++ 493,1 Base Libre
- 54D121
- CF3 C(O)CH2OH +++ 508,2 Base Libre
- 54D122
- CF3 C(O)CH2OH (Enantiómero 1) +++ 508,1 Base Libre
- 54D123
- CF3 C(O)CH2OH (Enantiómero 2) +++ 508,1 Base Libre
- Ej.
- R Actividad de rhSYK [M+H]+ Observado Forma(s)
- 54E-1
- CH(OH)CH3 (2R; cis) +++ 522,2 Sal formiato
- 54E-2
- CH(OH)CH3 (2S; cis) +++ 522,2 Sal formiato
81
- 113A-4
- 4-CH3 CH3 H/CH3 (isómero 1) H +++ 439 Base Libre
- 113A-5
- 4-CH3 CH3 H/CH3 (isómero 2) H +++ 439 Base Libre
- 113A-6
- 4-CH3 CH3 H/CH3 (isómero 3) H +++ 439 Base Libre
- 113A-7
- 4-CH3 CH3 H/CH3 (isómero 4) H +++ 439 Base Libre
- 113A-8
- 4-CH3 CH3 H/CH3 (isómero 1) CH3 +++ 453 Base Libre
- 113A-9
- 4-CH3 CH3 H/CH3 (isómero 2) CH3 ++ 453 Base Libre
- 113A-10
- 4-CH3 CH3 H/CH3 (isómero 3) CH3 +++ 453 Base Libre
- 113A-11
- 4-CH3 CH3 H/CH3 (isómero 4) CH3 +++ 453 Base Libre
- 113A-12
- 4-CH3 CH3 H/CH3 (isómero 5) CH3 ++ 453 Base Libre
- 113A-13
- 4-CH3 CH3 H/CH3 (isómero 6) CH3 ++ 453 Base Libre
- 113A-14
- 4-Et CH3 H/CH3 (isómero 1) H +++ 453,1 Base Libre
- 113A-15
- 4-Et CH3 H/CH3 (isómero 2) H +++ 453,1 Base Libre
- 113A-16
- 4-OCH3 CH3 H/CH3 (1S,2R,4R) H +++ 455 Sal formiato
- 113A-17
- 4-OCH3 CH3 H/CH3 (1R,2S,4S) H +++ 455 Sal formiato
- 113A-20
- 4-cPr CH3 H/CH3 (1R,2S,4S) H +++ 465 Sal formiato
- 113A-21
- 4-cPr CH3 H/CH3 (1S,2R,4R) H +++ 465,1 Sal formiato
- 113A-22
- 4-cPr CH3 H/CH3 H +++ 465,2 Sal TFA
- 113A-23
- 4-CH3 cPr H/CH3 (isómero 1) H +++ 465,1 Base Libre
- 113A-24
- 4-CH3 cPr H/CH3 (isómero 2) H +++ 465,1 Base Libre
- 113A-25
- 4-iPr CH3 H/CH3 (1S,2R,4R) H +++ 467,2 Base Libre
- 113A-26
- 4-iPr CH3 H/CH3 (1R,2S,4S) H +++ 467,2 Base Libre
- 113A-31
- 4-Et CH3 H/CH3 (isómero 1) Et +++ 481,1 Base Libre
- 113A-32
- 4-Et CH3 H/CH3 (isómero 2) Et +++ 481,1 Base Libre
- 113A-35
- 4-O-iPr CH3 H/CH3 (1R,2S,4S) H +++ 483 Sal formiato
- 113A-45
- 4-CF3 CH3 H/CH3 Et ++ 535 Base Libre
- 113A-49
- 4-Et CH3 CH3/CH3 (1S, 4R) H +++ 467,1 Base Libre
- 113A-51
- 4-cPr CH3 CH3/CH3 (cis) H +++ 479 Base Libre
- 113A-52
- 4-iPr CH3 CH3/CH3 (cis) H +++ 481 Base Libre
- 113A-53
- 4-Et CH3 CH3/CH3 (1S, 4R) CH3 +++ 481,1 Base Libre
- 113A-54
- 4-OCH3 CH3 CH3/CH3 (1S, 4R) CH3 +++ 483,1 Base Libre
- 113A-55
- 4-OCH3 CH3 CH3/CH3 (1R, 4S) CH3 +++ 483,2 Base Libre
- 113A-56
- 4-cPr CH3 CH3/CH3 (cis) CH3 +++ 493 Base Libre
- 113A-64
- 4-CF3* CH3 CH3/CH3 (1S,4R) H +++ 508,0 Base Libre
- 113A-65
- 4-CF3* CH3 CH3/CH3 (1S,4R) CH3 +++ 522,1 Base Libre
- R4a/R4b = H/CH3
- 113A-66
- 4-CH3 CH3 H/CH3 (isómero 1) H +++ 453 Base Libre
- 113A-67
- 4-CH3 CH3 H/CH3 (isómero 2) H +++ 453 Base Libre
- 113A-68
- 4-CH3 CH3 H/CH3 (isómero 3) H +++ 453 Base Libre
- 113A-69
- 4-CH3 CH3 H/CH3 (isómero 4) H +++ 453 Base Libre
- 113A-70
- 4-CH3 CH3 H/CH3 (isómero 1) Et +++ 481 Base Libre
- 113A-71
- 4-CH3 CH3 H/CH3 (isómero 2) Et +++ 481 Base Libre
- 113A-72
- 4-CH3 CH3 H/CH3 (isómero 3) Et +++ 481 Base Libre
- 113A-73
- 4-CH3 CH3 H/CH3 (isómero 4) Et +++ 481 Base Libre
- 113A-74
- 4-CH3 CH3 H/CH3 (isómero 1) H +++ 507 Base Libre
- 113A-75
- 4-CH3 CH3 H/CH3 (isómero 2) H +++ 507 Base Libre
- 113A-76
- 4-CH3 CH3 H/CH3 (isómero 3) H +++ 507 Base Libre
- 113A-77
- 4-CF3 CH3 H/CH3 (isómero 1) Et +++ 535 Base Libre
- 113A-78
- 4-CF3 CH3 H/CH3 (isómero 2) Et +++ 535 Base Libre
- 113A-79
- 4-CF3 CH3 H/CH3 (isómero 3) Et +++ 535 Base Libre
- 113A-80
- 4-CH3 CH3 H/H H +++ 439 Base Libre
- 113A-81
- 4-CH3 CH3 H/H (isómero 1) H +++ 439 Base Libre
- 113A-82
- 4-CH3 CH3 H/H (isómero 2) H +++ 439 Base Libre
- 113A-83
- 4-CH3 CH3 H/H (isómero 3) H +++ 439 Sal TFA
- 113A-84
- 4-CH3 CH3 H/H (isómero 4) H +++ 439 Sal TFA
- 113A-85
- 4-CH3 CH3 H/H (isómero 5) H +++ 439 Sal TFA
- 113A-86
- 4-CH3 CH3 H/H (isómero 6) H +++ 439 Sal TFA
- 113A-87
- 4-CH3 CH3 H/H Et +++ 467 Base Libre
- 113A-88
- 4-CF3 CH3 H/H H +++ 493 Base Libre
- 113A-89
- 4-CF3 CH3 H/H Et +++ 521 Base Libre
- R4a/R4b = H/OH
- 113A-90
- 4-CH3 CH3 H/H (isómero 1) H +++ 441 Base Libre
- 113A-91
- 4-CH3 CH3 H/H (isómero 2) H +++ 441 Base Libre
- R4a/R4b = CH3/CH3
95 TABLA 113B
- 113A-92
- 4-CH3 CH3 H/H H +++ 453 Base Libre
- * deuterado en la posición 6 de pirimidina
- Ejemplo
- R1 R2a/R2b R3 Actividad de rhSYK [M+H]+ Obs. Forma(s)
- 113B-1
- CH3 2,5-di(CH3) H +++ 453 Base Libre
- 113B-2
- CH3 2,5-di(CH3) (isómero 1) H +++ 453 Base Libre
- 113B-3
- CH3 2,5-di(CH3) (isómero 2) H +++ 453 Base Libre
- 113B-4
- CH3 2,5-di(CH3) (isómero 3) H +++ 453 Base Libre
- 113B-5
- CH3 2,5-di(CH3) (isómero 4) H +++ 453 Base Libre
- 113B-6
- CH3 2,5-di(CH3) (isómero 5) H +++ 453 Base Libre
- 113B-7
- CH3 2,5-di(CH3) Et +++ 481 Base Libre
- 113B-8
- CH3 2,5-di(CH3) (isómero 1) Et +++ 481 Base Libre
- 113B-9
- CH3 2,5-di(CH3) (isómero 2) Et +++ 481 Base Libre
- 113B-10
- CH3 2,5-di(CH3) (isómero 3) Et +++ 481 Base Libre
- 113B-11
- CH3 2,5-di(CH3) (isómero 4) Et ++ 481 Base Libre
- 113B-12
- CF3 2,5-di(CH3) H +++ 507 Base Libre
- 113B-13
- CF3 2,5-di(CH3) (isómero 1) H +++ 507 Base Libre
- 113B-14
- CF3 2,5-di(CH3) (isómero 2) H +++ 507 Base Libre
- 113B-15
- CF3 2,5-di(CH3) (isómero 3) H +++ 507 Base Libre
- 113B-16
- CF3 2,5-di(CH3) (isómero 4) H +++ 507 Base Libre
- 113B-17
- CF3 2,5-di(CH3) Et +++ 535 Base Libre
- 113B-18
- CF3 2,5-di(CH3) (isómero 1) Et +++ 535 Base Libre
- 113B-19
- CF3 2,5-di(CH3) (isómero 2) Et +++ 535 Base Libre
- 113B-20
- CF3 2,5-di(CH3) (isómero 3) Et ++ 535 Base Libre
- 113B-21
- CH3 2,6-di(CH3) H +++ 453 Base Libre
- 113B-22
- CH3 2,6-di(CH3) (trans,trans,trans) H +++ 453 Base Libre
- 113B-23
- CH3 2,6-di(CH3) iPr ++ 495 Base Libre
- 113B-24
- CF3 2,6-di(CH3) H +++ 507 Base Libre
- 113B-25
- CF3 2,6-di(CH3) (trans,trans,trans) H +++ 507 Base Libre
- 113B-26
- CF3 2,6-di(CH3) (isómero 1) iPr + 549 Base Libre
- 113B-27
- CF3 2,6-di(CH3) (isómero 2) iPr ++ 549 Base Libre
- 113B-28
- CH3 3,5-di(CH3) H +++ 453 Base Libre
- 113B-29
- CH3 3,5-di(CH3) Et +++ 481 Base Libre
- 113B-30
- CF3 3,5-di(CH3) H +++ 507 Base Libre
- 113B-31
- CF3 3,5-di(CH3) Et +++ 535 Base Libre
96 TABLA 113C
- n es 1 o 2 sustituyentes como se especifica en la Tabla.
- Ej.
- R1 R2 R3 X Actividad de rhSYK [M+H]+ Obs. Forma(s)
- 113C-2
- 4-cPr CH3 H C(O) +++ 436,2 Sal TFA
- 113C-3
- 4-CH(F)-CH3 CH3 H (enantiómero 1) C(O) +++ 442,1 Base Libre
- 113C-4
- 4-CH(F)-CH3 CH3 H (enantiómero 2) C(O) +++ 442,2 Base Libre
- 113C-7
- 4-CHF2 CH3 H C(O) +++ 446,1 Base Libre
- 113C-8
- 4-CF3 H H C(O) +++ 450,1 Sal TFA
- 113C-9
- 4-tBu CH3 H C(O) +++ 452,2 Base Libre
- 113C10
- 4-O-iPr CH3 H C(O) +++ 454,2 Base Libre
- 113C13
- 4-cPr CH3 H CH2 +++ 422,2 Base Libre
- 113C14
- 4-iPr CH3 H CH2 +++ 424,2 Base Libre
- 113C17
- 4-cPr CH3 BOC (enantiómero 1) CH2 +++ 522,3 Base Libre
- 113C18
- 4-cPr CH3 BOC (enantiómero 2) CH2 ++ 522,3 Base Libre
- 113C19
- 4-iPr CH3 BOC CH2 +++ 524,3 Base Libre
- 113C20
- 4-iPr CH3 BOC (enantiómero 1) CH2 ++ 524,3 Base Libre
- 113C21
- 4-iPr CH3 BOC (enantiómero 2) CH2 + 524,3 Base Libre
- Ej.
- Estructura Actividad de rhSYK [M+H]+ Obs. Forma(s)
- 113D-13
-
imagen87 +++ 443,1 Base Libre
97
TABLA 116A
- n es 1 o 2 sustituyentes como se especifica en la Tabla.
- Ej.
- R1 R2 X Actividad de rhSYK [M+H]+ Obs. Forma(s)
- 116A-3
- 4-iPr CO2H (cis) CH2 +++, +++ 453,2 Base Libre, Sal TFA
- 116A-6
- 4-tBu CO2H (cis) CH2 +++ 467,2 Sal TFA
- 116A-7
- 4-O-iPr CO2H (cis) CH2 +++ 469,2 Sal TFA
- 116A10
- 4-CH(F)CH3 CO2C(CH3)3 CH2 +++ 513,2 Base Libre
- 116A12
- 4-tBu CO2C(CH3)3 (cis) CH2 ++ 523,2 Base Libre
- 116A13
- 4-CF2CF3 CO2H (cis) CH2 +++ 529,1 Sal TFA
- 116A16
- 4-CF2CF3 CO2C(CH3)3 (cis) CH2 + 585,2 Sal TFA
- 116A18
- 4-CHF2 CO2H (isómero 1) CH(CH3) +++ 475,2 Base Libre
- 116A19
- 4-CHF2 CO2H (isómero 2) CH(CH3) +++ 475,2 Base Libre
- 116A20
- 4-tBu CO2H CH(CH3) +++ 481,2 Base Libre
- 116A21
- 4-O-iPr CO2H CH(CH3) +++, +++ 483,2 Base Libre, Sal formiato
- 116A30
- 4-CHF2 CO2H (1S, 4R) C(CH3)2 +++ 489,2 Base Libre
- 116A31
- 4-cBu CO2H (1S, 4R) C(CH3)2 +++ 493,2 Sal TFA
- 116A32
- 4-tBu CO2H (cis) C(CH3)2 +++ 495,2 Base Libre
- 116A33
- 4-O-iPr CO2H (1S,4R) C(CH3)2 +++ 497,2 Base Libre
- 116A37
- 4-CF3 CO2H (1S,4R) C(CH3)2 +++ 507,1 Sal TFA
- 116A39
- (R) 4-CH(F)CH3 CO2H (1S,4R) C(CH3)2 +++ 485,2 Base Libre
- 116A40
- (S) 4-CH(F)CH3 CO2H (1S,4R) C(CH3)2 +++ 485,2 Base Libre
99
Ejemplo 117
cis-4-hidroxi-1-metil-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexanocarboxamida
5
A una solución agitada de ácido cis-4-hidroxi-1-metil-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3tiazol-2-il]ciclohexanocarboxílico (442 mg, 0,90 mmol) en DMF (9,0 ml) se le añadieron cloruro de amonio (144 mg, 2,69 mmol), EDC (344 mg, 1,80 mmol), HOBt (243 mg, 1,80 mmol) y diisopropiletil amina (0,94 ml, 5,38 mmol). La 10 solución se dejó en agitación a temperatura ambiente durante 16 h. La reacción se diluyó con agua y se extrajo con EtOAc (3 x). Las capas orgánicas combinadas se lavaron con bicarbonato sódico acuoso saturado y salmuera, después se secaron (sulfato de magnesio), se filtraron y se concentraron. El residuo se purificó por cromatografía en columna para dar el compuesto del título en forma de un sólido de color blanco. ESI: [M + H]+ m/z 492,2. 1H RMN (500 MHz, CD3OD) δ 8,71 (d, J = 4,9, 1H), 8,03 (s, 1H), 7,91 (s, 1H), 7,44 (s, 1H), 7,13 (s, 2H), 2,37 (s, 3H), 2,22 (d,
Los compuestos en la siguiente Tabla o Tablas se prepararon de manera análoga a la descrita en el Ejemplo 117:
TABLA 117
- Ej.
- R1 R3 Actividad de rhSYK [M+H] + Obs. Forma(s)
- R2=H
- 117-1
-
CF3
imagen90 +++ 450,1 Base Libre
- 117-3
-
CF3
imagen91 +++ 492,2 Base Libre
- 117-4
- CF3 4-CONH2-cHex (cis) +++ 462,1 Base Libre
- 117-5
- CF3 4-CONH2-cHex (trans) +++ 462,1 Base Libre
- 117-7
-
CF3
imagen92 +++ 521,1 Base Libre
100
- 117-8
-
CF3
imagen93 +++ 492,2 Base Libre
- 117-9
-
CF3
imagen94 +++ 492,2 Base Libre
- 117-10
-
CF3
imagen95 +++ 492,2 Base Libre
- 117-11
-
CF3
imagen96 +++ 506,2 Base Libre
- 117-12
-
CF3
imagen97 +++ 506,2 Base Libre
- 117-13
- iPr +++ 509,2 Base Libre
- R2 = Br
Ejemplo 118
cis-4-hidroxi-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]-N-[3-(2-oxopirrolidin-1il)propil]ciclohexanocarboxamida
A N-(3-aminopropil)-2-pirrolidinona (14,1 µl, 0,12 mmol) se le añadió una solución de ácido cis-4-hidroxi-4-[5-(3-metil
10 5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]ciclohexanocarboxílico (48 mg, 0,1 mmol) en N,Ndimetilformamida (1 ml). Se añadió N,Ndiisopropiletilamina (35 µl, 0,2 mmol) y después la solución se enfrió a 0 ºC. Se añadió anhídrido cíclico del ácido 1-propanofosfónico (70 µl, 0,12 mmol), y la mezcla se calentó a temperatura ambiente y se agitó durante 16 h, se filtró, después se purificó por HPLC de fase inversa desencadenada en masa (C-18) para dar el producto del título (21,5 mg, 0,036 mmol, rendimiento del 36 %) en forma de un sólido de color
15 amarillo pálido. MS ESI: [M + H]+ m/z 603,2. 1H RMN (600 MHz, DMSO) δ 10,22 (s, 1H), 8,80 (d, J = 4,9, 1H), 7,91
101
dosis (10 µM a 0,508 nM) y ajuste de curva logística de cuatro parámetros usando el analizador de datos de ensayo de Merck. La actividad de rhSYK (CI50) se expresa como +++ (100 nM o menos), ++ (entre 100 y 1000 nM), + (entre 1 y 10 µM). CI50 para los compuestos representativos de la presente invención se proporciona como se muestra a continuación:
- Nombre del Compuesto
- CI50 de Syk
- 3-hidroxi-3-[5-(3-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]pirrolidin-1-carboxamida
- 11 nM
- Ácido {4-hidroxi-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]azepan-1il}acético
- 216 nM
- Ácido (1S,4R)-4-hidroxi-2,2-dimetil-4-(5-{3-metil-5-[(4-metilpirimidin-2-il)amino]-fenil}-1,3-tiazol-2il)ciclohexanocarboxílico
- 1 nM
- 1-(5- {3-[(4-terc-butilpirimidin-2-il)amino]-5-metilfenil}-1,3-tiazol-2-il)-ciclobutanol
- 25 nM
- (1S,4R)-N-(cianometil)-4-hidroxi-2,2-dimetil-4-(5-{3-metil-5-[(4-metilpirimidin-2-il)amino]fenil}-1,3-tiazol-2il)ciclohexanocarboxamida
- 2 nM
- cis-4-hidroxi-4-[5-(3-metil-5-{[4-(pentafluoroetil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2il]ciclohexanocarboxilato de cistercbutilo
- 2427 nM
- Ácido (1S,4R)-4-hidroxi-2,2-dimetil-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2il]ciclohexanocarboxílico
- < 0,5 nM
- Ácido trans-4-hidroxi-1-metil-4-[5-(3-{[4-(trifluorometil)pirimidin-2-il]amino}-fenil)-1,3-tiazol-2il]ciclohexanocarboxílico
- 4 nM
- Ácido cis-4-hidroxi-1-metil-4-[5-(3-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2il]ciclohexanocarboxílico
- 2 nM
- cis-4-[(hidroxiacetil)amino]-1-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il] ciclohexanocarboxamida
- 2 nM
- (1S,4R)-4-hidroxi-2,2-dimetil-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2-il]-N[3-(2-oxopirrolidin-1-il)propil]ciclohexanocarboxamida
- 1 nM
- Ácido (1S,2R,4R)-4-hidroxi-2-metil-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2il]ciclohexanocarboxílico y enantiómero
- 1 nM, < 0,5 nM
- Ácido (1S,4R)-4-metoxi-2,2-dimetil-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2il]ciclohexanocarboxílico
- 2 nM
- Ácido (1R,4S)-4-hidroxi-2,2-dimetil-4-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}fenil)-1,3-tiazol-2il]ciclohexanocarboxílico
- 2 nM
- Clorhidrato de N{3-[2-(1-aminociclobutil)-1,3-tiazol-5-il]-5-metilfenil}-4-ciclopropil-pirimidin-2-amina
- 3 nM
- (1R,4S)-4-hidroxi-2,2-dimetil-4-[5-(3-metil-5-{[4-(trifluorometil)-pirimidin-2-il]amino}fenil)-1,3-tiazol-2il]ciclohexanocarboxilato de etilo
- 49 nM
- 5-(aminometil)-5-[5-(3-metil-5-{[4-(trifluorometil)pirimidin-2-il]amino}-fenil)-1,3-tiazol-2-il]azepan-2-ona
- 50 nM
- Ácido (1S,4R)-4-{5-[3-({4-[(1S)-1-fluoroetil]pirimidin-2-il}amino)-5-metilfenil]-1,3-tiazol-2-il}-4-hidroxi-2,2dimetilciclohexanocarboxílico
- <0,5 nM
- Ácido (1S,4R)-4-{5-[3-({4-[(1R)-1-fluoroetil]pirimidin-2-il}amino)-5-metilfenil]-1,3-tiazol-2-il}-4-hidroxi-2,2dimetilciclohexanocarboxílico
- <0,5 nM
120
Claims (1)
-
imagen1 imagen2 imagen3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28726709P | 2009-12-17 | 2009-12-17 | |
| US287267P | 2009-12-17 | ||
| PCT/US2010/060454 WO2011075515A1 (en) | 2009-12-17 | 2010-12-15 | Aminopyrimidines as syk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2609040T3 true ES2609040T3 (es) | 2017-04-18 |
Family
ID=43502894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10801736.9T Active ES2609040T3 (es) | 2009-12-17 | 2010-12-15 | Aminopirimidinas como inhibidores de Syk |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8759366B2 (es) |
| EP (1) | EP2513098B1 (es) |
| JP (2) | JP5242857B2 (es) |
| KR (1) | KR101445012B1 (es) |
| CN (1) | CN102858767B (es) |
| AR (1) | AR080672A1 (es) |
| AU (1) | AU2010331927B2 (es) |
| BR (1) | BR112012014703B1 (es) |
| CA (1) | CA2782889C (es) |
| CL (1) | CL2012001627A1 (es) |
| CO (1) | CO6551728A2 (es) |
| CR (1) | CR20120331A (es) |
| DO (1) | DOP2012000166A (es) |
| EA (1) | EA022790B1 (es) |
| EC (1) | ECSP12011982A (es) |
| ES (1) | ES2609040T3 (es) |
| GE (1) | GEP20146125B (es) |
| GT (1) | GT201200202A (es) |
| MA (1) | MA33926B1 (es) |
| MX (1) | MX2012007154A (es) |
| NI (1) | NI201200108A (es) |
| NZ (1) | NZ600673A (es) |
| PE (1) | PE20121480A1 (es) |
| PH (1) | PH12012501225A1 (es) |
| SG (1) | SG181803A1 (es) |
| TN (1) | TN2012000288A1 (es) |
| TW (1) | TW201132637A (es) |
| WO (2) | WO2011075517A1 (es) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2512246B1 (en) | 2009-12-17 | 2015-09-30 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
| AU2010331927B2 (en) * | 2009-12-17 | 2013-10-10 | Merck Canada Inc. | Aminopyrimidines as Syk inhibitors |
| EP2516434B1 (en) | 2009-12-23 | 2015-05-27 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
| CN102812022B (zh) | 2010-01-12 | 2016-02-03 | Ab科学有限公司 | 噻唑和噁唑激酶抑制剂 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| WO2012151137A1 (en) * | 2011-05-04 | 2012-11-08 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
| AU2012253885A1 (en) * | 2011-05-10 | 2013-10-31 | Merck Sharp & Dohme Corp. | Aminopyrimidines as Syk inhibitors |
| WO2012154518A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
| CA2834062A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
| JP2014159375A (ja) * | 2011-06-15 | 2014-09-04 | Takeda Chem Ind Ltd | アゼパン化合物 |
| WO2012177714A1 (en) | 2011-06-22 | 2012-12-27 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
| CN104125957B (zh) * | 2011-12-21 | 2016-05-25 | 拜耳知识产权有限责任公司 | 取代的苄基吡唑 |
| US8906889B2 (en) | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| US9096579B2 (en) | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
| US8889854B2 (en) | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| EP2863913B1 (en) | 2012-06-20 | 2018-09-12 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
| WO2013192125A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| WO2013192088A1 (en) * | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| US9376418B2 (en) | 2012-06-22 | 2016-06-28 | Merck Sharp & Dohme Corp. | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| EP2884982B1 (en) * | 2012-08-20 | 2017-09-20 | Merck Sharp & Dohme Corp. | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| WO2014048065A1 (en) * | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| US20150284381A1 (en) * | 2012-11-07 | 2015-10-08 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
| US20150299125A1 (en) * | 2012-11-07 | 2015-10-22 | Merck Sharp & Dohme Corp. | Prodrug bipyridylaminopyridines as syk inhibitors |
| EP2931281B1 (en) | 2012-12-12 | 2018-01-17 | Merck Sharp & Dohme Corp. | Amino-pyrimidine-containing spleen tyrosine kinase inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EP2934525B1 (en) * | 2012-12-21 | 2019-05-08 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
| NZ629037A (en) | 2013-03-15 | 2017-04-28 | Infinity Pharmaceuticals Inc | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| EP2988744A4 (en) * | 2013-04-26 | 2016-11-02 | Merck Sharp & Dohme | THIAZOLSUBSTITUTED AMINOHETEROARYLE AS MILZTYROSINKINASE INHIBITOR |
| WO2014176216A1 (en) * | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
| KR20160013204A (ko) | 2013-05-30 | 2016-02-03 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료 |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3964507A1 (en) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US20160244452A1 (en) | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9670196B2 (en) | 2013-12-20 | 2017-06-06 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors |
| EP3083559B1 (en) * | 2013-12-20 | 2021-03-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| WO2015094997A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| WO2015138273A1 (en) | 2014-03-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP3954710A3 (en) | 2015-04-02 | 2022-07-20 | Intervet International B.V. | Antibodies to canine interleukin-4 receptor alpha |
| TWI706937B (zh) * | 2015-06-08 | 2020-10-11 | 美商艾斯特隆製藥公司 | 製備蛋白質去乙醯酶抑制劑之方法 |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN107235873B (zh) * | 2017-07-04 | 2018-11-06 | 中节能万润股份有限公司 | 一种美司钠的制备方法 |
| CN107573263B (zh) * | 2017-08-14 | 2020-04-07 | 大连理工大学 | 一种ω-取代缩二脲类化合物的合成方法 |
| MX2020002745A (es) | 2017-09-11 | 2020-10-14 | Cyteir Therapeutics Inc | Inhibidores de rad51. |
| AU2018350683A1 (en) | 2017-10-19 | 2020-04-02 | Bayer Animal Health Gmbh | Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals |
| US11040975B2 (en) | 2017-12-08 | 2021-06-22 | Merck Sharp & Dohme Corp. | Carbocyclic nucleoside reverse transcriptase inhibitors |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| KR102328682B1 (ko) | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| PH12021552205A1 (en) | 2019-03-25 | 2022-06-13 | Cyteir Therapeutics Inc | Combinations of rad51 and parp inhibitors |
| HRP20231310T1 (hr) | 2019-05-10 | 2024-02-02 | Deciphera Pharmaceuticals, Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene |
| HUE065486T2 (hu) | 2019-05-10 | 2024-05-28 | Deciphera Pharmaceuticals Llc | Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai |
| ES3072710T3 (en) | 2019-06-17 | 2026-07-03 | Deciphera Pharmaceuticals Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| MX2022006475A (es) | 2019-11-29 | 2022-09-07 | Lupin Ltd | Compuestos triciclicos sustituidos. |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021123092A1 (en) | 2019-12-20 | 2021-06-24 | Intervet International B.V. | Bispecific caninized antibodies for treating atopic dermatitis |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN115003798B (zh) * | 2020-06-17 | 2025-08-01 | 兰迪·莱曼·阿伦 | 用于检测分析物的方法和试剂盒 |
| EP4185279A4 (en) | 2020-07-24 | 2024-05-01 | Secura Bio, Inc. | TREATING CANCER WITH PI3-KINASE ISOFORM MODULATORS |
| JP7905331B2 (ja) | 2020-10-15 | 2026-08-14 | インターベット インターナショナル ベー． フェー． | イヌインターロイキン－３１受容体アルファに対するイヌ化抗体 |
| KR20230154789A (ko) * | 2020-11-06 | 2023-11-09 | 액티노젠 메디컬 리미티드 | 헤테로고리 메탄온 화합물 및 그의 아자-비시클로 중간체의 제조 공정 |
| AU2022246081A1 (en) | 2021-03-23 | 2023-10-12 | Halia Therapeutics, Inc. | Pyrimidine derivatives useful as lrrk2 kinase inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US20240368249A1 (en) | 2021-08-20 | 2024-11-07 | Intervet Inc. | Fusion proteins for treating atopic dermatitis |
| CN114105958B (zh) * | 2021-12-03 | 2022-11-22 | 郑州大学第一附属医院 | 一组含羟肟酸的2-苯氨基嘧啶类衍生物及其应用 |
| AU2022409610A1 (en) | 2021-12-16 | 2024-05-30 | Intervet International B.V. | Caninized antibodies to canine interleukin-31 receptor alpha 1 |
| WO2024107746A1 (en) * | 2022-11-15 | 2024-05-23 | Larkspur Biosciences | Inhibitors and degraders of pip4k protein |
| UY40908A (es) | 2023-10-06 | 2025-03-31 | Sumitomo Chemical Co | Compuestos de biarilo y método para controlar enfermedades vegetales |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59609305D1 (de) | 1995-11-17 | 2002-07-11 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Herstellung |
| EP1386922B1 (en) | 1996-12-03 | 2012-04-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
| GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
| US6960584B2 (en) | 2001-04-10 | 2005-11-01 | Merck & Co., Inc. | Inhibitors of Akt activity |
| WO2002083139A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
| JP4361276B2 (ja) | 2001-04-10 | 2009-11-11 | メルク エンド カムパニー インコーポレーテッド | Ａｋｔ活性の阻害物質 |
| WO2002083140A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
| WO2002096905A1 (en) | 2001-06-01 | 2002-12-05 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinases |
| CA2450934A1 (en) | 2001-06-19 | 2002-12-27 | Marco Dodier | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| GB0123951D0 (en) | 2001-10-05 | 2001-11-28 | Glaxo Group Ltd | Therapies for treating respiratory diseases |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| WO2003086404A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Fused quinoxaline derivatives as inhibitors of akt activity |
| WO2003086279A2 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| JP4451136B2 (ja) | 2002-04-08 | 2010-04-14 | メルク エンド カムパニー インコーポレーテッド | Ａｋｔ活性阻害薬 |
| CA2480800C (en) | 2002-04-08 | 2008-09-23 | Mark T. Bilodeau | Inhibitors of akt activity |
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| JP2006524688A (ja) | 2003-03-25 | 2006-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチアゾール |
| ATE396731T1 (de) | 2003-03-25 | 2008-06-15 | Vertex Pharma | Thiazole zur verwendung als inhibitoren von protein-kinasen |
| BRPI0416128B8 (pt) | 2003-11-03 | 2021-06-22 | Glaxo Group Ltd | dispositivo de dispensação de fluido |
| US7345043B2 (en) | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| BRPI0607062A2 (pt) * | 2005-02-28 | 2009-08-04 | Japan Tobacco Inc | composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos |
| CN101166734A (zh) * | 2005-02-28 | 2008-04-23 | 日本烟草产业株式会社 | 具有Syk抑制活性的新型的氨基吡啶化合物 |
| WO2006129100A1 (en) | 2005-06-03 | 2006-12-07 | Glaxo Group Limited | Novel compounds |
| GB0520838D0 (en) * | 2005-10-13 | 2005-11-23 | Glaxo Group Ltd | Novel compounds |
| ATE534632T1 (de) | 2006-04-11 | 2011-12-15 | Vertex Pharma | Thiazole, imidazole und pyrazole als proteinkinasehemmer |
| WO2008024634A1 (en) * | 2006-08-25 | 2008-02-28 | Smithkline Beecham Corporation | Pyrimdine compounds useful as kinase inhibitors |
| JP5208123B2 (ja) | 2006-12-08 | 2013-06-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| TW200840581A (en) | 2007-02-28 | 2008-10-16 | Astrazeneca Ab | Novel pyrimidine derivatives |
| CA2686378C (en) | 2007-05-04 | 2012-07-24 | Irm Llc | Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors |
| CN101903357A (zh) | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | 作为pkc抑制剂的环状胺取代的嘧啶二胺 |
| EP2200436B1 (en) | 2007-09-04 | 2015-01-21 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| HRP20170317T1 (hr) | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| US20100056524A1 (en) | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
| CA2723205C (en) | 2008-04-16 | 2017-03-14 | Portola Pharmaceuticals, Inc. | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors |
| AU2010331927B2 (en) | 2009-12-17 | 2013-10-10 | Merck Canada Inc. | Aminopyrimidines as Syk inhibitors |
| CN102812022B (zh) * | 2010-01-12 | 2016-02-03 | Ab科学有限公司 | 噻唑和噁唑激酶抑制剂 |
| DE102010000842A1 (de) * | 2010-01-13 | 2011-07-14 | Robert Bosch GmbH, 70469 | Batterie, Batteriesystem und Verfahren zur Verbindung einer Mehrzahl von Batterien |
-
2010
- 2010-12-15 AU AU2010331927A patent/AU2010331927B2/en not_active Ceased
- 2010-12-15 GE GEAP201012792A patent/GEP20146125B/en unknown
- 2010-12-15 EP EP10801736.9A patent/EP2513098B1/en active Active
- 2010-12-15 ES ES10801736.9T patent/ES2609040T3/es active Active
- 2010-12-15 KR KR1020127018540A patent/KR101445012B1/ko not_active Expired - Fee Related
- 2010-12-15 CA CA2782889A patent/CA2782889C/en active Active
- 2010-12-15 CN CN201080064916.3A patent/CN102858767B/zh not_active Expired - Fee Related
- 2010-12-15 JP JP2012544746A patent/JP5242857B2/ja not_active Expired - Fee Related
- 2010-12-15 EA EA201290515A patent/EA022790B1/ru not_active IP Right Cessation
- 2010-12-15 PH PH1/2012/501225A patent/PH12012501225A1/en unknown
- 2010-12-15 US US13/516,455 patent/US8759366B2/en not_active Expired - Fee Related
- 2010-12-15 MA MA35069A patent/MA33926B1/fr unknown
- 2010-12-15 BR BR112012014703-0A patent/BR112012014703B1/pt not_active IP Right Cessation
- 2010-12-15 WO PCT/US2010/060463 patent/WO2011075517A1/en not_active Ceased
- 2010-12-15 WO PCT/US2010/060454 patent/WO2011075515A1/en not_active Ceased
- 2010-12-15 MX MX2012007154A patent/MX2012007154A/es active IP Right Grant
- 2010-12-15 NZ NZ600673A patent/NZ600673A/xx not_active IP Right Cessation
- 2010-12-15 SG SG2012045118A patent/SG181803A1/en unknown
- 2010-12-15 PE PE2012000838A patent/PE20121480A1/es not_active Application Discontinuation
- 2010-12-15 US US12/968,608 patent/US8551984B2/en not_active Expired - Fee Related
- 2010-12-17 TW TW099144560A patent/TW201132637A/zh unknown
- 2010-12-17 AR ARP100104724A patent/AR080672A1/es not_active Application Discontinuation
-
2012
- 2012-06-05 TN TNP2012000288A patent/TN2012000288A1/en unknown
- 2012-06-15 CL CL2012001627A patent/CL2012001627A1/es unknown
- 2012-06-15 DO DO2012000166A patent/DOP2012000166A/es unknown
- 2012-06-15 NI NI201200108A patent/NI201200108A/es unknown
- 2012-06-15 GT GT201200202A patent/GT201200202A/es unknown
- 2012-06-15 CO CO12101568A patent/CO6551728A2/es active IP Right Grant
- 2012-06-18 CR CR20120331A patent/CR20120331A/es unknown
- 2012-06-19 EC ECSP12011982 patent/ECSP12011982A/es unknown
-
2013
- 2013-04-02 JP JP2013076543A patent/JP5829644B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-17 US US14/255,480 patent/US20140243290A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1303067C (zh) | 用作半光氨酸蛋白酶可逆抑制剂的螺杂环腈 | |
| AU782246B2 (en) | Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases | |
| CA2379747C (en) | Novel succinate derivative compounds useful as cysteine protease inhibitors | |
| CA2994203C (en) | Azaspiro compounds as muscarinic agonists | |
| US9890138B2 (en) | Diaminopyrimidine derivatives and processes for the preparation thereof | |
| WO2005108358A2 (en) | Pyrrolidine derivatives useful as bace inhibitors | |
| ES2348002T3 (es) | Derivados de pirrolidina como antagonistas dobles de los receptores nk1/nk3. | |
| US20090264431A1 (en) | Novel cathepsin c inhibitors and their use | |
| DE102007020492A1 (de) | Substituierte Sulfonamid-Derivate | |
| US9221756B2 (en) | Pyrrole derivatives | |
| US7585885B2 (en) | Pyrrolidine derivatives useful as BACE inhibitors | |
| JP5568137B2 (ja) | 含フッ素カルバマート基を有するアミノ酸アミド誘導体の製造方法、その製造中間体、及びエチレンジアミン誘導体の製造方法 | |
| JPWO2006080519A1 (ja) | ジアミン誘導体 |